Alembic shoots up on Pristiq generic approval and Ranbaxy tie
This article was originally published in Scrip
Executive Summary
Shares of Alembic Pharmaceuticals rose 15% on Indian bourses after the company said that it had received US FDA approval for its NDA for desvenlafaxine base extended release tablets, a bioequivalent version of Pfizer's antidepressant Pristiq, and also firmed up a marketing alliance with Ranbaxy's US arm for the product.